Literature DB >> 8921446

'Unqualified success' and 'unmitigated failure': number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events.

M Schulzer1, G B Mancini.   

Abstract

BACKGROUND: Common indices for the quantal assessment of treatment efficacy are reviewed. The absolute risk reduction is a practical index for public health considerations. Its reciprocal has been termed the 'Number Needed to Treat' (NNT), representing the health effort that must on average be expended to accomplish one tangible treatment target. We extend the NNT to evaluate outcome combinations of treatment benefits versus treatment harms.
METHODS: We describe the mathematical context of the NNT, and extend it to evaluate outcome combinations (treatment success/failure with/without treatment-induced adverse effects) in a treated population. These extensions are carried out assuming either independence or positive association between treatment benefit and treatment harm. A method is provided for calculating the standard errors of these extended NNT values. Applications to cost-effectiveness analysis are discussed.
RESULTS: We calculate NNT in three recent therapeutic studies. The results of a trial of the prevention of strokes with warfarin in patients with non-valvular atrial fibrillation are analysed to evaluate treatment success (stroke prevention) against treatment-induced bleeds. An NNT-related cost-benefit analysis is also carried out. We also analyse the results of a study of two modalities of chemotherapeutic treatment in small-cell lung cancer, and of two modalities of surgical intervention in the treatment of cholelithiasis.
CONCLUSIONS: The NNT are useful in direct evaluation of outcome-specific treatment benefits versus treatment-induced harms. They may also be used in cost-effectiveness analyses and are helpful in guiding public health programmes towards the identification of optimal treatment strategies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8921446     DOI: 10.1093/ije/25.4.704

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  9 in total

Review 1.  New technologies in cancer and their assessment. The clinical surgeon's point of view.

Authors:  Javier Escrig Sos; David Martínez Ramos
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.405

2.  Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.

Authors:  David W Dodick; Giorgio Sandrini; Paul Williams
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

3.  Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis.

Authors:  L D Bos; L R Schouten; L A van Vught; M A Wiewel; D S Y Ong; O Cremer; A Artigas; I Martin-Loeches; A J Hoogendijk; T van der Poll; J Horn; N Juffermans; C S Calfee; M J Schultz
Journal:  Thorax       Date:  2017-04-27       Impact factor: 9.139

4.  Comparisons are odious.

Authors:  Viraj Suvarna
Journal:  Perspect Clin Res       Date:  2014-10

5.  Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial.

Authors:  Kevin J Harrington; Robert Hi Andtbacka; Frances Collichio; Gerald Downey; Lisa Chen; Zsolt Szabo; Howard L Kaufman
Journal:  Onco Targets Ther       Date:  2016-11-16       Impact factor: 4.147

Review 6.  Number Needed to Treat in Multiple Sclerosis Clinical Trials.

Authors:  Macaulay Okwuokenye; Annie Zhang; Amy Pace; Karl E Peace
Journal:  Neurol Ther       Date:  2017-02-07

7.  Designing noninferiority tuberculosis treatment trials: Identifying practical advantages for drug regimens with acceptable effectiveness.

Authors:  Piero L Olliaro; Michel Vaillant
Journal:  PLoS Med       Date:  2019-07-12       Impact factor: 11.069

8.  A tool to balance benefit and harm when deciding about adjuvant therapy.

Authors:  A M Knops; A Goossens; M P M Burger; L J A Stalpers; D T Ubbink
Journal:  Br J Cancer       Date:  2009-03-24       Impact factor: 7.640

9.  Net efficacy adjusted for risk (NEAR): a simple procedure for measuring risk:benefit balance.

Authors:  José N Boada; Carlos Boada; Mar García-Sáiz; Marcelino García; Eduardo Fernández; Eugenio Gómez
Journal:  PLoS One       Date:  2008-10-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.